PAK4 Inhibition Improves PD-1 Blockade Immunotherapy
Demographics (2)
- age - Subject age at thearpy start (phv00420542.v1.p1)
- sex - Gender of participant (phv00420543.v1.p1)
Disease Events (6)
- BODY_SITE - Anatomycal tumor location (phv00420551.v1.p1)
- disease_status - TNM Staging at therapy start (phv00420544.v1.p1)
- IS_TUMOR - Tumor status (phv00420553.v1.p1)
- orr - Overall Response by RECIST 1.1 criteria (phv00420546.v1.p1)
- os - Overal Survival (phv00420547.v1.p1)
- PRIMARY_METASTATIC_TUMOR - Primary or metastatic tumor (phv00420555.v1.p1)
Other (19)
- ANALYTE_TYPE - Analyte Type (phv00420552.v1.p1)
- Biopsy 1 ID - Sample_ID of biopsy 1 (phv00427375.v1.p1)
- Biopsy 2 ID - Sample_ID of biopsy 2 (phv00427377.v1.p1)
- Biopsy 3 ID - Sample_ID of biopsy 3 (phv00427379.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00420538.v1.p1)
- GEO Sample_ID - Sample ID listed in GEO (phv00420549.v1.p1)
- HISTOLOGICAL_TYPE - Cell or tissue type or subtype of sample (phv00420554.v1.p1)
- PRESERVATION_METHOD - Sample preservation method (phv00420556.v1.p1)
- Response by biopsy 1 - Response as determined by changes in biopsy 1 size (phv00427374.v1.p1)
- Response by biopsy 2 - Response as determined by changes in biopsy 2 size (phv00427376.v1.p1)
- Response by biopsy 3 - Response as determined by changes in biopsy 3 size (phv00427378.v1.p1)
- Sample_ID - De-identified Sample ID (phv00420548.v1.p1)
- SAMPLE_ID - De-identified Sample ID (phv00420550.v1.p1)
- SAMPLE_ID - Sample ID (phv00420540.v1.p1)
- SEQUENCING_CENTER - Name of the center which conducted sequencing (phv00420557.v1.p1)
- SUBJECT_ID - De-identified Subject ID (phv00420541.v1.p1)
- SUBJECT_ID - Subject ID (phv00420537.v1.p1)
- SUBJECT_ID - Subject ID (phv00420539.v1.p1)
- treatment - Therapy (phv00420545.v1.p1)